Rapamycin- and paclitaxel-eluting stents for prevention of cardiovascular events：effectiveness and safety

Fang Ling-hai; Ying Hai-rong; Sun Wei

doi:10.3969/j.issn.2095-4344

Abstract：BACKGROUND:Rapamycin- and paclitaxel-eluting stents have become widely used treatment methods for coronary artery disease. But there are rarely reports about their effectiveness and safety in the prevention of cardiovascular events. OBJECTIVE:To explore the effectiveness and safety of rapamycin- and paclitaxel-eluting stents for prevention of cardiovascular events. METHODS:Totaly 117 patients with coronary artery diseases were enroled, including 89 males and 28 females, aged 35-81 years. Rapamycin-eluting stent implantation was done in 59 cases, while paclitaxel-eluting stent implantation in 58 cases. Al the patients were folowed up for 12 months postoperatively, and the incidence of adverse cardiac events and the incidence of thrombosis were recorded to analyze the efficacy and safety of these two kinds of drug-eluting stents of prevention of cardiovascular events. RESULTS AND CONCLUSION: These two kinds of drug-eluting stents had good biocompatibility with the host, and no stent shedding and shift occurred. At 9 months of folow-up, the incidence of thrombosis was 3.4% in the rapamycin-eluting stent group and 3.5% in the paclitaxel-eluting stent group, and there was no difference between the two groups (P > 0.05). At 12 months of folow-up, the incidence of adverse cardiac events was 13.6% in the rapamycin-eluting stent group and 13.8% in the paclitaxel-eluting stent group, and there was also no <br> difference between the two groups (P > 0.05). These findings indicate that rapamycin- and paclitaxel-eluting stents is effective and safe to prevent cardiovascular events.